Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PASKALIUM vs MYAMBUTOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.
Treatment of multidrug-resistant tuberculosis (MDR-TB) in combination with other antituberculosis agents
Treatment of pulmonary tuberculosis in combination with other antituberculosis agents,Treatment of extrapulmonary tuberculosis
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (Cr Cl <30 m L/min).
Terminal elimination half-life: 3-4 hours in normal renal function; prolonged to 7-15 hours in renal impairment.
PASKALIUM is hydrolyzed in the gastrointestinal tract to PAS; PAS is primarily metabolized via acetylation (N-acetyltransferase) and conjugation with glycine.
Partially metabolized in the liver via dealkylation to an aldehyde intermediate, which is further oxidized to a dicarboxylic acid. Approximately 50% of the drug is excreted unchanged in urine.
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
Renal: 50% unchanged drug; 20% as metabolite (ethambutol carboxylic acid); 15% as aldehyde intermediate; 15% unknown; fecal: <10%.
98% bound, primarily to alpha-1-acid glycoprotein (AAG) and albumin.
20-30% bound to albumin.
Vd: 0.8-1.2 L/kg; suggests extensive tissue distribution, likely due to high lipophilicity.
1.6 L/kg; distributes widely into tissues, including erythrocytes and cerebrospinal fluid (with inflamed meninges).
Oral: 85-90% (first-pass metabolism minimal); intramuscular: 95%; intravenous: 100%.
Oral: approximately 80% absorbed.
GFR >60: no adjustment; GFR 30-60: 250 mg daily; GFR <30: 125 mg daily.
Cr Cl 30-60 m L/min: 15-20 mg/kg daily; Cr Cl 10-29 m L/min: 15 mg/kg every 24-36 hours; Cr Cl <10 m L/min: 15 mg/kg every 48 hours.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg daily; Child-Pugh C: 125 mg daily.
No specific Child-Pugh based adjustments; use with caution in severe hepatic impairment.
10 mg/kg/day orally in divided doses every 12 hours.
15-25 mg/kg orally once daily (max 1 g/day for children weighing <20 kg, otherwise 2.5 g/day).
Start at 250 mg daily; adjust based on renal function.
Consider reduced initial dose based on renal function; monitor for optic neuritis.
None.
MYAMBUTOL may cause optic neuritis and decreased visual acuity, which may be dose-related and reversible upon discontinuation. Not recommended for use in children under 13 years of age.
May cause gastrointestinal irritation, hepatotoxicity, and hypersensitivity reactions. Monitor liver function and renal function during therapy.
Optic neuritis (monitor visual acuity and color discrimination); hepatic toxicity; renal impairment (dose adjustment required); interaction with aluminum-containing antacids (decreased absorption).
Hypersensitivity to para-aminosalicylic acid or any component of the formulation,Severe renal impairment (Cr Cl < 30 m L/min)
Hypersensitivity to ethambutol; optic neuritis (unless benefit outweighs risk); children under 13 years of age (relative contraindication).
Avoid high-potassium foods (bananas, oranges, spinach, potatoes, tomatoes). Use of potassium-containing salt substitutes is contraindicated.
No significant food interactions. However, administration with food may reduce gastrointestinal upset. Concurrent use with aluminum-containing antacids may decrease absorption; separate by at least 2 hours.
PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcomes. First trimester: no known risk. Second trimester: no known risk. Third trimester: maternal electrolyte disturbances may affect fetal heart rate and uterine contractility.
Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant increase in major malformations. However, due to the risk of optic neuritis in the mother, use during pregnancy should be cautious and only if clearly needed.
Potassium is a normal constituent of breast milk. PASKALIUM is compatible with breastfeeding. M/P ratio: not applicable as potassium is endogenous. No adverse effects on nursing infant reported.
Ethambutol is excreted into human breast milk in low concentrations; the estimated infant dose is approximately 2-4% of the maternal weight-adjusted dose. The milk-to-plasma ratio is approximately 0.57. The American Academy of Pediatrics considers ethambutol compatible with breastfeeding. Monitor the infant for signs of optic neuritis or gastrointestinal effects.
Pregnancy may alter potassium distribution due to increased plasma volume. Dosing should be individualized based on serum potassium levels. No fixed dose adjustment required; titrate to maintain normal potassium levels (3.5-5.0 m Eq/L).
No specific dose adjustments are routinely recommended during pregnancy. However, pharmacokinetic changes in pregnancy (increased volume of distribution, enhanced renal clearance) may reduce serum concentrations; therapeutic drug monitoring is not standard but may be considered. Adjust dose based on renal function; usual dose is 15-25 mg/kg/day, not to exceed 2.5 g/day.
PASKALIUM is a potassium-sparing diuretic used for hypertension and edema. Monitor serum potassium regularly; avoid in severe renal impairment or hyperkalemia. Coadministration with ACE inhibitors or NSAIDs increases hyperkalemia risk.
MYAMBUTOL (ethambutol) is a bacteriostatic agent used primarily in combination therapy for tuberculosis. Monitor for optic neuritis, which can cause decreased visual acuity, color blindness, and visual field defects; baseline and monthly visual acuity and color discrimination tests are mandatory. Dose adjustments required in renal impairment (Cr Cl <30 m L/min). Avoid in children <13 years old due to inability to monitor vision. May cause hyperuricemia; monitor uric acid levels in patients with gout.
Take exactly as prescribed; do not skip doses or double up.,Avoid potassium-rich foods and salt substitutes unless directed.,Report muscle weakness, irregular heartbeat, or signs of hyperkalemia.,May cause dizziness; avoid driving until effects known.
Take exactly as prescribed, usually once daily, with or without food.,Report any changes in vision immediately, such as blurred vision, difficulty seeing colors, or blind spots.,Avoid consuming alcohol; may increase risk of liver toxicity.,Do not stop taking this medication even if you feel better; complete full course to prevent resistance.,This drug may cause numbness or tingling in hands or feet; report these symptoms.,Inform your doctor if you have kidney disease, gout, or eye problems before starting treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PASKALIUM vs MYAMBUTOL, answered by our medical review team.
PASKALIUM is a Antitubercular Agent that works by PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.. MYAMBUTOL is a Antitubercular Agent that works by Inhibits arabinosyl transferase, an enzyme involved in cell wall synthesis of mycobacteria, leading to inhibition of cell growth.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PASKALIUM and MYAMBUTOL depend on the specific clinical indication. These are both Antitubercular Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PASKALIUM is: PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.. The standard adult dose of MYAMBUTOL is: 15-25 mg/kg orally once daily (max 2.5 g/day); usual dose 20 mg/kg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PASKALIUM and MYAMBUTOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PASKALIUM is classified as Category C. PASKALIUM (potassium chloride) is not teratogenic. No fetal risks are expected at therapeutic doses. However, maternal hypokalemia or hyperkalemia may adversely affect fetal outcom. MYAMBUTOL is classified as Category C. Ethambutol (Myambutol) is classified as FDA Pregnancy Category B. Animal studies have not demonstrated teratogenic effects. Human data are limited but do not suggest a significant . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.